| 1 |
Shao J, Wang Y, Hu L, Zhang L, Lyu C. Lower risk of hepatocellular carcinoma with tenofovir than entecavir in antiviral treatment-naïve chronic hepatitis B patients: a systematic review and meta-analysis involving 90,897 participants. Clin Exp Med 2023. [PMID: 36648567 DOI: 10.1007/s10238-023-00990-w] [Reference Citation Analysis]
|
| 2 |
Dusheiko G, Agarwal K, Maini MK. New Approaches to Chronic Hepatitis B. N Engl J Med 2023;388:55-69. [PMID: 36599063 DOI: 10.1056/NEJMra2211764] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 3 |
Zhao T, Yang Z, Yu J, Lu J, Li L, Xu X, Cao H, Zheng S. Comparing Long-Term Outcomes of Entecavir and Tenofovir Disoproxil Fumarate in Liver Transplant Patients. Advanced Gut & Microbiome Research 2022;2022:1-9. [DOI: 10.1155/2022/4779960] [Reference Citation Analysis]
|
| 4 |
Belaiba Z, Ayouni K, Gdoura M, Kammoun Rebai W, Touzi H, Sadraoui A, Hammemi W, Yacoubi L, Abdelati S, Hamzaoui L, Msaddak Azzouz M, Chouikha A, Triki H. Whole genome analysis of hepatitis B virus before and during long-term therapy in chronic infected patients: Molecular characterization, impact on treatment and liver disease progression. Front Microbiol 2022;13:1020147. [DOI: 10.3389/fmicb.2022.1020147] [Reference Citation Analysis]
|
| 5 |
Kim JH, Kim JH, Choe WH, Kwon SY, Yoo BC, Yoon EL, Kang SH. Switching from Tenofovir-Based Combination Therapy to Tenofovir Monotherapy in Multidrug-Experienced Chronic Hepatitis B Patients: a 5-Year Experience at Two Centers. Antimicrob Agents Chemother 2022;66:e0027522. [PMID: 35867571 DOI: 10.1128/aac.00275-22] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 6 |
Won J, Lee AR, Dezhbord M, Lee DR, Kim SH, Kim JC, Park S, Kim N, Jae B, Kim K. Susceptibility of Drug Resistant Hepatitis B Virus Mutants to Besifovir. Biomedicines 2022;10:1637. [DOI: 10.3390/biomedicines10071637] [Reference Citation Analysis]
|
| 7 |
Ozdemir YE, Sahin Ozdemir M, Bayramlar OF, Surme S, Yildiz Kaya S, Karaali R, Balkan II, Mete B, Saltoglu N, Tabak F. Long-term follow-up of treatment-naïve HBeAg-negative patients with chronic hepatitis B. Ir J Med Sci 2022. [PMID: 35715665 DOI: 10.1007/s11845-022-03066-y] [Reference Citation Analysis]
|
| 8 |
Liu T, Sun Q, Gu J, Cen S, Zhang Q. Characterization of the tenofovir resistance-associated mutations in the hepatitis B virus isolates across genotypes A to D. Antiviral Research 2022. [DOI: 10.1016/j.antiviral.2022.105348] [Reference Citation Analysis]
|
| 9 |
Msomi N, Parboosing R, Wilkinson E, Giandhari J, Govender K, Chimukangara B, Mlisana KP. Persistent Hepatitis B Viraemia with Polymerase Mutations among HIV/HBV Co-Infected Patients on HBV-Active ART in KwaZulu-Natal, South Africa. Viruses 2022;14. [PMID: 35458518 DOI: 10.3390/v14040788] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 10 |
Holan M, Tucker K, Dyatkina N, Liu H, Kinkade A, Wang G, Jin Z, Prhavc M. Synthesis and Anti-Hepatitis B Activities of 3′-Fluoro-2′-Substituted Apionucleosides. Molecules 2022;27:2413. [DOI: 10.3390/molecules27082413] [Reference Citation Analysis]
|
| 11 |
Lim YS, Seto WK, Kurosaki M, Fung S, Kao JH, Hou J, Gordon SC, Flaherty JF, Yee LJ, Zhao Y, Agarwal K, Lampertico P. Review article: switching patients with chronic hepatitis B to tenofovir alafenamide-a review of current data. Aliment Pharmacol Ther 2022;55:921-43. [PMID: 35178711 DOI: 10.1111/apt.16788] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 12 |
Winckelmann A, Fahnøe U, Bajpai P, Dalegaard MI, Lundh A, Ryom L, Bukh J, Weis N. Novel hepatitis B virus reverse transcriptase mutations in patients with sustained viremia despite long-term tenofovir treatment. Journal of Clinical Virology 2022. [DOI: 10.1016/j.jcv.2022.105159] [Reference Citation Analysis]
|
| 13 |
Kim JC, Lee HY, Lee AR, Dezhbord M, Lee DR, Kim SH, Won J, Park S, Kim NY, Shin JJ, Kim SG, Kim YS, Yoo J, Kim K. Identification and Characterization of Besifovir-Resistant Hepatitis B Virus Isolated from a Chronic Hepatitis B Patient. Biomedicines 2022;10:282. [DOI: 10.3390/biomedicines10020282] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 14 |
Man X, Wei R. Advancements in the prevention of hepatitis B recurrence by nucleos(t)ide analogue monotherapies after liver transplantation. Eur J Inflamm 2022;20:1721727X2211392. [DOI: 10.1177/1721727x221139254] [Reference Citation Analysis]
|
| 15 |
Premkumar M, Chawla YK. Should We Treat Immune Tolerant Chronic Hepatitis B? Lessons from Asia. J Clin Exp Hepatol 2022;12:144-54. [PMID: 35068795 DOI: 10.1016/j.jceh.2021.08.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 16 |
Qi L, Yang M, Chang D, Zhao W, Zhang S, Du Y, Li Y. A DNA Nanoflower-Assisted Separation-Free Nucleic Acid Detection Platform with a Commercial Pregnancy Test Strip. Angew Chem Int Ed Engl 2021;60:24823-7. [PMID: 34432346 DOI: 10.1002/anie.202108827] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 17 |
Yamashige D, Hosaka T, Suzuki F, Fujiyama S, Kawamura Y, Sezaki H, Akuta N, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H. Effectiveness of tenofovir alafenamide for chronic hepatitis B patients with a poor response to the previously used nucleos(t)ide analogs. J Gastroenterol 2021;56:1008-21. [PMID: 34596753 DOI: 10.1007/s00535-021-01826-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 18 |
Qi L, Yang M, Chang D, Zhao W, Zhang S, Du Y, Li Y. A DNA Nanoflower‐Assisted Separation‐Free Nucleic Acid Detection Platform with a Commercial Pregnancy Test Strip. Angew Chem 2021;133:25027-31. [DOI: 10.1002/ange.202108827] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 19 |
Ringlander J, Andersson ME, Prakash K, Larsson SB, Lindh M. Deep sequencing of hepatitis B virus using Ion Torrent fusion primer method. J Virol Methods 2022;299:114315. [PMID: 34648822 DOI: 10.1016/j.jviromet.2021.114315] [Reference Citation Analysis]
|
| 20 |
Dezanet LNC, Miailhes P, Lascoux-Combe C, Chas J, Maylin S, Gabassi A, Rougier H, Delaugerre C, Lacombe K, Boyd A. Persistent HBV replication and serological response during up to 15 years of tenofovir-based antiretroviral therapy in HIV/HBV-coinfected patients: a multicentre prospective cohort study. J Antimicrob Chemother 2021;76:3009-19. [PMID: 34458919 DOI: 10.1093/jac/dkab294] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 21 |
Higuera-de-la-Tijera F, Castro-Narro GE, Velarde-Ruiz Velasco JA, Cerda-Reyes E, Moreno-Alcántar R, Aiza-Haddad I, Castillo-Barradas M, Cisneros-Garza LE, Dehesa-Violante M, Flores-Calderón J, González-Huezo MS, Márquez-Guillén E, Muñóz-Espinosa LE, Pérez-Hernández JL, Ramos-Gómez MV, Sierra-Madero J, Sánchez-Ávila JF, Torre-Delgadillo A, Torres R, Marín-López ER, Kershenobich D, Wolpert-Barraza E. Asociación Mexicana de Hepatología A.C. Clinical guideline on hepatitis B. Rev Gastroenterol Mex (Engl Ed) 2021;86:403-32. [PMID: 34483073 DOI: 10.1016/j.rgmxen.2021.04.002] [Reference Citation Analysis]
|
| 22 |
Jeong S, Cho Y, Park SM, Kim W. Differential Effectiveness of Tenofovir and Entecavir for Prophylaxis of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Depending on Coexisting Cirrhosis and Prior Exposure to Antiviral Therapy: A Systematic Review and Meta-analysis. J Clin Gastroenterol 2021;55:e77-86. [PMID: 33883516 DOI: 10.1097/MCG.0000000000001548] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 23 |
Lee JH, Kim HS. Current laboratory tests for diagnosis of hepatitis B virus infection. Int J Clin Pract 2021;:e14812. [PMID: 34487586 DOI: 10.1111/ijcp.14812] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 24 |
Yao X, Huang S, Zhou H, Tang SH, Qin JP. Clinical efficacy of antiviral therapy in patients with hepatitis B-related cirrhosis after transjugular intrahepatic portosystemic shunt. World J Gastroenterol 2021; 27(30): 5088-5099 [PMID: 34497437 DOI: 10.3748/wjg.v27.i30.5088] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 25 |
Higuera-de-la-Tijera F, Castro-Narro GE, Velarde-Ruiz Velasco JA, Cerda-Reyes E, Moreno-Alcántar R, Aiza-Haddad I, Castillo-Barradas M, Cisneros-Garza LE, Dehesa-Violante M, Flores-Calderón J, González-Huezo MS, Márquez-Guillén E, Muñóz-Espinosa LE, Pérez-Hernández JL, Ramos-Gómez MV, Sierra-Madero J, Sánchez-Ávila JF, Torre-Delgadillo A, Torres R, Marín-López ER, Kershenobich D, Wolpert-Barraza E. Asociación Mexicana de Hepatología A.C. Clinical guideline on hepatitis B. Rev Gastroenterol Mex 2021:S0375-0906(21)00061-6. [PMID: 34384668 DOI: 10.1016/j.rgmx.2021.04.002] [Reference Citation Analysis]
|
| 26 |
Zou W, Qian F, Jin F, Li D, Chen J. Characterization of mutations in the reverse transcriptase region of hepatitis B virus in treated and untreated chronic hepatitis B patients. Trans R Soc Trop Med Hyg 2021;115:870-7. [PMID: 33236067 DOI: 10.1093/trstmh/traa142] [Reference Citation Analysis]
|
| 27 |
Mokaya J, Vasylyeva TI, Barnes E, Ansari MA, Pybus OG, Matthews PC. Global prevalence and phylogeny of hepatitis B virus (HBV) drug and vaccine resistance mutations. J Viral Hepat 2021;28:1110-20. [PMID: 33893696 DOI: 10.1111/jvh.13525] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 28 |
Torre P, Aglitti A, Masarone M, Persico M. Viral hepatitis: Milestones, unresolved issues, and future goals. World J Gastroenterol 2021; 27(28): 4603-4638 [PMID: 34366625 DOI: 10.3748/wjg.v27.i28.4603] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 29 |
Cornberg M, Sandmann L, Protzer U, Niederau C, Tacke F, Berg T, Glebe D, Jilg W, Wedemeyer H, Wirth S, Höner Zu Siederdissen C, Lynen-Jansen P, van Leeuwen P, Petersen J; Collaborators:. S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion – (AWMF-Register-Nr. 021-11). Z Gastroenterol 2021;59:691-776. [PMID: 34255317 DOI: 10.1055/a-1498-2512] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 30 |
Qu B, Brown RJP. Strategies to Inhibit Hepatitis B Virus at the Transcript Level. Viruses 2021;13:1327. [PMID: 34372533 DOI: 10.3390/v13071327] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 31 |
Chen R, Pei S, Chen Y, Tan L, Xue Y, Liu S, Huang Y, Fan X. Suboptimal Response to Tenofovir Alafenamide in Two Patients With HBeAg-Positive Hepatitis B: A Case Report. Front Med (Lausanne) 2021;8:701061. [PMID: 34307428 DOI: 10.3389/fmed.2021.701061] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 32 |
Dezanet LNC, Miailhes P, Lascoux-combe C, Chas J, Maylin S, Gabassi A, Rougier H, Delaugerre C, Lacombe K, Boyd A. Persistent HBV replication and serological response during up to fifteen years of tenofovir-based antiretroviral therapy in HIV-hepatitis B coinfected patients: a multicenter prospective cohort study.. [DOI: 10.1101/2021.07.01.21259560] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 33 |
Delfino CM, Giorgio M, García G, Puch SS, Outon E, Mathet VL. Drug-resistant and immune-escape hepatitis B virus mutants, occult hepatitis B infection and coinfections in public hospital patients from Argentina. Virus Genes 2021;57:327-37. [PMID: 34091827 DOI: 10.1007/s11262-021-01850-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 34 |
Kiruthika S, Bhat R, Dash R, Rathore AS, Vivekanandan P, Jayaram B. A novel piperazine derivative that targets hepatitis B surface antigen effectively inhibits tenofovir resistant hepatitis B virus. Sci Rep 2021;11:11723. [PMID: 34083665 DOI: 10.1038/s41598-021-91196-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 35 |
Zanella I, Zizioli D, Castelli F, Quiros-Roldan E. Tenofovir, Another Inexpensive, Well-Known and Widely Available Old Drug Repurposed for SARS-COV-2 Infection. Pharmaceuticals (Basel) 2021;14:454. [PMID: 34064831 DOI: 10.3390/ph14050454] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
|
| 36 |
Suzuki F, Sezaki H, Hosaka T, Suzuki Y, Fujiyama S, Kawamura Y, Akuta N, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Mineta R, Suzuki Y, Kumada H. Virologic analysis of tenofovir resistance in a patient with chronic hepatitis B experiencing viral breakthrough during combination treatment with tenofovir disoproxil fumarate and entecavir. Hepatol Res 2021;51:503-8. [PMID: 33462964 DOI: 10.1111/hepr.13618] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 37 |
Shang J, Liu H, Wen Q, M Ise R, Tu Y, Bai L, Tang H. Analysis of long-term safety and efficacy of nucleos(t)ide analogue therapy for chronic hepatitis B throughout pregnancy. Int J Infect Dis 2021;105:626-31. [PMID: 33722684 DOI: 10.1016/j.ijid.2021.03.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 38 |
Liu Y, Chen R, Liu W, Si L, Li L, Li X, Yao Z, Liao H, Wang J, Li Y, Zhao J, Xu D. Investigation of multidrug-resistance mutations of hepatitis B virus (HBV) in a large cohort of chronic HBV-infected patients with treatment of nucleoside/nucleotide analogs. Antiviral Res 2021;189:105058. [PMID: 33711338 DOI: 10.1016/j.antiviral.2021.105058] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 39 |
McNaughton AL, Lemoine M, van Rensburg C, Matthews PC. Extending treatment eligibility for chronic hepatitis B virus infection. Nat Rev Gastroenterol Hepatol 2021;18:146-7. [PMID: 33323992 DOI: 10.1038/s41575-020-00398-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 40 |
Lee AR, Cho JY, Kim JC, Dezhbord M, Choo SY, Ahn CH, Kim NY, Shin JJ, Park S, Park ES, Won J, Kim DS, Lee JH, Kim KH. Distinctive HBV Replication Capacity and Susceptibility to Tenofovir Induced by a Polymerase Point Mutation in Hepatoma Cell Lines and Primary Human Hepatocytes. Int J Mol Sci 2021;22:1606. [PMID: 33562603 DOI: 10.3390/ijms22041606] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 41 |
Choi WM, Choi J, Lim YS. Effects of Tenofovir vs Entecavir on Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2021;19:246-258.e9. [PMID: 32407970 DOI: 10.1016/j.cgh.2020.05.008] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 21.5] [Reference Citation Analysis]
|
| 42 |
Song DS, Kim W, Ahn SH, Yim HJ, Jang JY, Kweon YO, Cho YK, Kim YJ, Hong GY, Kim DJ, Jung YK, Sohn JH, Lee JW, Park SJ, Lee BS, Kim JH, Kim HS, Yoon SK, Kim MY, Lee KS, Lim YS, Lee WS, Yang JM, Kim KH, Han KH, Um SH. Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial. Clin Mol Hepatol 2021;27:346-59. [PMID: 33493393 DOI: 10.3350/cmh.2020.0307] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 43 |
Komatsu H, Inui A, Yoshio S, Fujisawa T. Pharmacotherapy options for managing hepatitis B in children. Expert Opin Pharmacother 2021;22:449-67. [PMID: 33090882 DOI: 10.1080/14656566.2020.1841165] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 44 |
Liu Y, Chang S, Martin R, Flaherty J, Mo H, Feierbach B. Characterization of Hepatitis B virus polymerase mutations A194T and CYEI and tenofovir disoproxil fumarate or tenofovir alafenamide resistance. J Viral Hepat 2021;28:30-9. [PMID: 32894807 DOI: 10.1111/jvh.13397] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 45 |
Dusheiko G. Unmet Needs in Clinical Research Hepatitis B. Hepatitis B Virus and Liver Disease 2021. [DOI: 10.1007/978-981-16-3615-8_3] [Reference Citation Analysis]
|
| 46 |
Zhou K, Terrault N. Opioid use disorder and Chronic Hepatitis B. The Opioid Epidemic and Infectious Diseases 2021. [DOI: 10.1016/b978-0-323-68328-9.00007-2] [Reference Citation Analysis]
|
| 47 |
Kim B, Terrault NA. Hepatitis B and Hepatitis D Infections in the Transplant Setting. Emerging Transplant Infections 2021. [DOI: 10.1007/978-3-030-25869-6_37] [Reference Citation Analysis]
|
| 48 |
Lee JH. Old hepatitis B virus never dies: It just hides itself within the host genome. Clin Mol Hepatol 2021;27:107-9. [PMID: 33353287 DOI: 10.3350/cmh.2020.0324] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 49 |
Kim MA, Kim SU, Sinn DH, Jang JW, Lim YS, Ahn SH, Shim JJ, Seo YS, Baek YH, Kim SG, Kim YS, Kim JH, Choe WH, Yim HJ, Lee HW, Kwon JH, Lee SW, Jang JY, Kim HY, Park Y, Kim GA, Yang H, Lee HA, Koh M, Lee YS, Kim M, Chang Y, Kim YJ, Yoon JH, Zoulim F, Lee JH. Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study. Gut 2020;69:2214-22. [PMID: 32209606 DOI: 10.1136/gutjnl-2019-320015] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 50 |
Yim HJ, Suh SJ, Jung YK, Hwang SG, Seo YS, Um SH, Lee SH, Kim YS, Jang JY, Kim IH, Kim HS, Kim JH, Lee YS, Yoon EL, Song MJ, Park JY. Tenofovir-based combination therapy or monotherapy for multidrug-resistant chronic hepatitis B: Long-term data from a multicenter cohort study. J Viral Hepat 2020;27:1306-18. [PMID: 32706461 DOI: 10.1111/jvh.13363] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 51 |
Rodríguez M, Buti M, Esteban R, Lens S, Prieto M, Suárez E, García-samaniego J. Consensus document of the Spanish Association for Study of the Liver on the treatment of hepatitis B virus infection (2020). Gastroenterología y Hepatología (English Edition) 2020;43:559-587. [DOI: 10.1016/j.gastre.2020.03.008] [Reference Citation Analysis]
|
| 52 |
Mokaya J, Vasylyeva TI, Barnes E, Ansari MA, Pybus OG, Matthews PC. Global prevalence and phylogeny of hepatitis B virus (HBV) drug and vaccine resistance mutations.. [DOI: 10.1101/2020.10.07.329391] [Reference Citation Analysis]
|
| 53 |
Revill PA, Tu T, Netter HJ, Yuen LKW, Locarnini SA, Littlejohn M. The evolution and clinical impact of hepatitis B virus genome diversity. Nat Rev Gastroenterol Hepatol 2020;17:618-34. [PMID: 32467580 DOI: 10.1038/s41575-020-0296-6] [Cited by in Crossref: 69] [Cited by in F6Publishing: 64] [Article Influence: 23.0] [Reference Citation Analysis]
|
| 54 |
Yuen L, Revill PA, Rosenberg G, Wagner J, Littlejohn M, Bayliss J, Jackson K, Tan SK, Gaggar A, Kitrinos K, Subramanian M, Gane E, Chan HLY, Li X, Bowden S, Locarnini S, Thompson A. HBV variants are common in the 'immune-tolerant' phase of chronic hepatitis B. J Viral Hepat 2020;27:1061-70. [PMID: 32384174 DOI: 10.1111/jvh.13318] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 55 |
Lau KCK, Burak KW, Coffin CS. Impact of Hepatitis B Virus Genetic Variation, Integration, and Lymphotropism in Antiviral Treatment and Oncogenesis. Microorganisms 2020;8:E1470. [PMID: 32987867 DOI: 10.3390/microorganisms8101470] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 56 |
Huang BX, Liu Y, Fan ZP, Si LL, Chen RJ, Wang J, Luo D, Wang FS, Xu DP, Liu XG. Investigation of immune escape-associated mutations of hepatitis B virus in patients harboring hepatitis B virus drug-resistance mutations. World J Gastroenterol 2020; 26(35): 5314-5327 [PMID: 32994690 DOI: 10.3748/wjg.v26.i35.5314] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 57 |
Lee H, Park Y, Choi Y. Overview of anti-Hepatitis B virus agents. jbv 2020;50:141-9. [DOI: 10.4167/jbv.2020.50.3.141] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 58 |
Yim HJ, Kim JH, Park JY, Yoon EL, Park H, Kwon JH, Sinn DH, Lee SH, Lee JH, Lee HW. Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop. Clin Mol Hepatol. 2020;26:411-429. [PMID: 32854458 DOI: 10.3350/cmh.2020.0049] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 59 |
Rodríguez M, Buti M, Esteban R, Lens S, Prieto M, Suárez E, García-Samaniego J. Consensus document of the Spanish Association for Study of the Liver on the treatment of hepatitis B virus infection (2020). Gastroenterol Hepatol 2020;43:559-87. [PMID: 32778356 DOI: 10.1016/j.gastrohep.2020.03.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 60 |
Marlet J, Lier C, Roch E, Maugey M, Moreau A, Combe B, Lefeuvre S, d'Alteroche L, Barbereau D, Causse X, Bastides F, Bachelier MN, Brand D, Gaudy-Graffin C. Revisiting HBV resistance to entecavir with a phenotypic approach. Antiviral Res 2020;181:104869. [PMID: 32735901 DOI: 10.1016/j.antiviral.2020.104869] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 61 |
Phung TTB, Chu SV, Vu ST, Pham HT, Nguyen HM, Nguyen HD, Le NT, Nguyen DV, Truong PT, Vu VTT, Nguyen ATV. COLD-PCR Method for Early Detection of Antiviral Drug-Resistance Mutations in Treatment-Naive Children with Chronic Hepatitis B. Diagnostics (Basel) 2020;10:E491. [PMID: 32708399 DOI: 10.3390/diagnostics10070491] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 62 |
Qian F, Zou W, Jin F, Li D, Shen Y. Prevalence of Potential Resistance Related Variants Among Chinese Chronic Hepatitis B Patients Not Receiving Nucleos(T)ide Analogues. Infect Drug Resist 2020;13:2407-16. [PMID: 32765014 DOI: 10.2147/IDR.S249476] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 63 |
Mokaya J, Maponga TG, McNaughton AL, Van Schalkwyk M, Hugo S, Singer JB, Sreenu VB, Bonsall D, de Cesare M, Andersson M, Gabriel S, Taljaard J, Barnes E, Preiser W, Van Rensburg C, Matthews PC. Evidence of tenofovir resistance in chronic hepatitis B virus (HBV) infection: An observational case series of South African adults. J Clin Virol 2020;129:104548. [PMID: 32663786 DOI: 10.1016/j.jcv.2020.104548] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 64 |
Park S, Park ES, Koo JE, Park YK, Lee AR, Dezhbord M, Cho ES, Ahn SH, Kim DH, Lee JH, Lee HC, Kim KH. Entecavir-resistant hepatitis B virus decreases surface antigenicity: A full genome and functional characterization. Liver Int 2020;40:1564-77. [PMID: 32216026 DOI: 10.1111/liv.14446] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 65 |
Mokaya J, McNaughton AL, Bester PA, Goedhals D, Barnes E, Marsden BD, Matthews PC. Hepatitis B virus resistance to tenofovir: fact or fiction? Wellcome Open Res. 2020;5:151. [PMID: 33869791 DOI: 10.12688/wellcomeopenres.15992.1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 66 |
Chen R, Liu Y, Luo D, Si L, Huang B, Wang J, Li X, Cheng F, Xu D, Duan C. Hepatitis B virus mutation pattern rtA181S+T184I+M204I may contribute to multidrug resistance in clinical practice: Analysis of a large cohort of Chinese patients. Antiviral Res 2020;180:104852. [PMID: 32569703 DOI: 10.1016/j.antiviral.2020.104852] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 67 |
Archampong T, Ojewale O, Bears K, Chen Y, Lartey M, Sagoe KW, Obo-Akwa A, Gong Y, Langaee T, Kwara A. Brief Report: Relationship Between ABCC4 SNPs and Hepatitis B Virus Suppression During Tenofovir-Containing Antiretroviral Therapy in Patients With HIV/HBV Coinfection. J Acquir Immune Defic Syndr 2019;82:421-5. [PMID: 31335591 DOI: 10.1097/QAI.0000000000002136] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 68 |
Lenci I, Milana M, Grassi G, Manzia TM, Gazia C, Tisone G, Angelico R, Baiocchi L. Hepatitis B virus recurrence after liver transplantation: An old tale or a clear and present danger? World J Gastroenterol 2020; 26(18): 2166-2176 [PMID: 32476783 DOI: 10.3748/wjg.v26.i18.2166] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 69 |
Maponga TG, McNaughton AL, van Schalkwyk M, Hugo S, Nwankwo C, Taljaard J, Mokaya J, Smith DA, van Vuuren C, Goedhals D, Gabriel S, Andersson MI, Preiser W, van Rensburg C, Matthews PC. Treatment advantage in HBV/HIV coinfection compared to HBV monoinfection in a South African cohort. J Infect 2020;81:121-30. [PMID: 32360882 DOI: 10.1016/j.jinf.2020.04.037] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 70 |
Mokaya J, Maponga TG, Mcnaughton AL, Van Schalkwyk M, Hugo S, Singer JB, Sreenu VB, Bonsall D, de Cesare M, Andersson M, Gabriel S, Taljaard J, Barnes E, Preiser W, Van Rensburg C, Matthews PC. Evidence of Tenofovir Resistance in Chronic Hepatitis B Virus (HBV) Infection: An Observational Case Series of South African Adults.. [DOI: 10.1101/2020.03.18.20038216] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 71 |
Jiang D, Zeng H, Wang X. Response to comments on: Entecavir resistance mutations rtL180M/T184L/M204V combined with rtA200V lead to tenofovir resistance. Liver Int 2020;40:730. [PMID: 31811784 DOI: 10.1111/liv.14319] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 72 |
Liang B, Zheng X. Comments on 'Entecavir resistance mutations rtL180M/T184L/M204V combined with rtA200V lead to tenofovir resistance'. Liver Int 2020;40:729. [PMID: 31705783 DOI: 10.1111/liv.14290] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 73 |
Buti M, Roade L, Riveiro-Barciela M, Esteban R. Optimal management of chronic hepatitis B patients receiving nucleos(t)ide analogues. Liver Int 2020;40 Suppl 1:15-21. [PMID: 32077604 DOI: 10.1111/liv.14367] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 74 |
Jo E, Ryu DK, König A, Park S, Cho Y, Park SH, Kim TH, Yoon SK, Ryu WS, Cechetto J, Windisch MP. Identification and characterization of a novel hepatitis B virus pregenomic RNA encapsidation inhibitor. Antiviral Res 2020;175:104709. [PMID: 31940474 DOI: 10.1016/j.antiviral.2020.104709] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 75 |
Kim B, Terrault NA. Hepatitis B and Hepatitis D Infections in the Transplant Setting. Emerging Transplant Infections 2020. [DOI: 10.1007/978-3-030-01751-4_37-1] [Reference Citation Analysis]
|
| 76 |
Jiang D, Wang J, Zhao X, Li Y, Zhang Q, Song C, Zeng H, Wang X. Entecavir resistance mutations rtL180M/T184L/M204V combined with rtA200V lead to tenofovir resistance. Liver Int 2020;40:83-91. [PMID: 31498528 DOI: 10.1111/liv.14241] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 77 |
Yip TC, Wong VW, Chan HL, Tse YK, Lui GC, Wong GL. Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China. Gastroenterology 2020;158:215-225.e6. [PMID: 31574268 DOI: 10.1053/j.gastro.2019.09.025] [Cited by in Crossref: 116] [Cited by in F6Publishing: 122] [Article Influence: 38.7] [Reference Citation Analysis]
|
| 78 |
Lee JH, Kim KH. Reply to: "In response to identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients.". J Hepatol 2019;71:1260-1. [PMID: 31585739 DOI: 10.1016/j.jhep.2019.08.030] [Reference Citation Analysis]
|
| 79 |
Blackard JT, Kwara A, Sherman KE. In response to identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients. J Hepatol 2019;71:1259-60. [PMID: 31564447 DOI: 10.1016/j.jhep.2019.07.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 80 |
Weissmann L, Picone CM, Gouvêa MSG, Ferreira PRA, Viana MSVB, Pinho JRR, Cassenote AJF, Segurado AC. Hepatitis B viremia in HIV-coinfected individuals under antiretroviral therapy. Braz J Infect Dis 2019;23:441-50. [PMID: 31715124 DOI: 10.1016/j.bjid.2019.10.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 81 |
Chang L, Hou Y, Zhu L, Wang Z, Chen G, Shu C, Liu Y. Veliparib overcomes multidrug resistance in liver cancer cells. Biochem Biophys Res Commun 2020;521:596-602. [PMID: 31679697 DOI: 10.1016/j.bbrc.2019.10.141] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 82 |
Maponga TG, Mcnaughton AL, Van Schalkwyk M, Hugo S, Nwankwo C, Taljaard J, Mokaya J, Smith DA, van Vuuren C, Goedhals D, Gabriel S, Andersson MI, Preiser W, van Rensburg C, Matthews PC. Treatment advantage in HBV/HIV coinfection compared to HBV monoinfection in a South African cohort.. [DOI: 10.1101/19007963] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 83 |
Tafesh ZH, Brown RS. Management of Virologic Failure in Patients with Chronic Hepatitis B Treated with Nucleos(t)ide Analogues. Curr Hepatology Rep 2019;18:363-369. [DOI: 10.1007/s11901-019-00483-z] [Reference Citation Analysis]
|
| 84 |
Luo D, Liu Y, Chen R, Niu M, Liu L, Li X, Li Q, Huang B, Wang J, Xu D, Lin S. Investigation of hepatitis B virus (HBV) rtS78T/sC69* mutation in a large cohort of chronic HBV-infected patients with nucleoside/nucleotide analogue treatment. Antiviral Res. 2019;170:104579. [PMID: 31398372 DOI: 10.1016/j.antiviral.2019.104579] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 85 |
Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol 2019;25:93-159. [PMID: 31185710 DOI: 10.3350/cmh.2019.1002] [Cited by in Crossref: 113] [Cited by in F6Publishing: 124] [Article Influence: 28.3] [Reference Citation Analysis]
|
| 86 |
Yoon EL, Yim HJ. Updated Treatment of Chronic Hepatitis B. Korean J Med 2019;94:252-262. [DOI: 10.3904/kjm.2019.94.3.252] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 87 |
Antivirals. Reactions Weekly 2019;1755:44-44. [DOI: 10.1007/s40278-019-62598-4] [Reference Citation Analysis]
|
| 88 |
[DOI: 10.1101/19009563] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
|
